Prothena Corporation plc (NASDAQ:PRTA – Get Free Report) major shareholder William Scully bought 50,000 shares of Prothena stock in a transaction that occurred on Tuesday, November 17th. The stock was purchased at an average price of $8.09 per share, for a total transaction of $404,500.00. Following the acquisition, the insider directly owned 1,027,000 shares of the company’s stock, valued at $8,308,430. The trade was a 5.12% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Prothena Trading Down 2.1%
PRTA stock opened at $8.22 on Friday. The stock has a 50-day moving average price of $8.44 and a two-hundred day moving average price of $9.14. Prothena Corporation plc has a 12-month low of $7.70 and a 12-month high of $11.80. The company has a market cap of $422.10 million, a PE ratio of -17.13, a price-to-earnings-growth ratio of 4.17 and a beta of -0.20.
Prothena (NASDAQ:PRTA – Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The biotechnology company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.09). The firm had revenue of $0.62 million for the quarter, compared to analyst estimates of $9.58 million. Prothena had a negative return on equity of 9.98% and a negative net margin of 45.44%. Equities analysts forecast that Prothena Corporation plc will post 0.06 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Several equities research analysts recently issued reports on the stock. Wall Street Zen downgraded shares of Prothena from a “buy” rating to a “hold” rating in a research note on Saturday, July 25th. Weiss Ratings downgraded Prothena from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, October 29th. HC Wainwright began coverage on Prothena in a research report on Friday, November 6th. They set a “strong-buy” rating on the stock. Finally, UBS Group reiterated a “buy” rating on shares of Prothena in a research note on Friday, July 24th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $20.00.
Check Out Our Latest Report on PRTA
Institutional Trading of Prothena
Hedge funds have recently made changes to their positions in the stock. American Century Companies Inc. increased its stake in shares of Prothena by 1.4% in the third quarter. American Century Companies Inc. now owns 91,901 shares of the biotechnology company’s stock worth $770,000 after buying an additional 1,257 shares during the last quarter. Allspring Global Investments Holdings LLC acquired a new stake in Prothena in the third quarter valued at $239,000. Chicago Partners Investment Group LLC boosted its stake in Prothena by 59.8% during the 3rd quarter. Chicago Partners Investment Group LLC now owns 25,779 shares of the biotechnology company’s stock valued at $211,000 after acquiring an additional 9,650 shares during the last quarter. Pinnacle Associates Ltd. boosted its stake in Prothena by 6.2% during the 3rd quarter. Pinnacle Associates Ltd. now owns 61,507 shares of the biotechnology company’s stock valued at $515,000 after acquiring an additional 3,589 shares during the last quarter. Finally, Versant Capital Management Inc boosted its stake in Prothena by 179.1% during the 3rd quarter. Versant Capital Management Inc now owns 5,704 shares of the biotechnology company’s stock valued at $48,000 after acquiring an additional 3,660 shares during the last quarter. Institutional investors and hedge funds own 97.08% of the company’s stock.
About Prothena
Prothena Corporation plc is a clinical-stage biotechnology company developing treatments for diseases associated with protein misfolding and dysfunction. Its research focuses on using antibodies and other biologic approaches to target proteins implicated in neurological and systemic disorders. The company’s pipeline has included programs for Parkinson’s disease, Alzheimer’s disease and AL amyloidosis. Its investigational therapies include prasinezumab, developed in collaboration with Roche, and programs targeting amyloid beta and transthyretin-related disease.
Read More
- Five stocks we like better than Prothena
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.
